Please assess the completion status of the following clinical trial:

Trial Title: Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented HIV infection confirmed by western blot or HIV RNA.~2. At least 18 years of age.~3. Less than 1 week of prior antiretroviral therapy.~4. In the opinion of the investigator, patients should be clinically stable. Patients may be on chronic suppressive therapy for opportunistic infections such as MAC or CMV.~5. Patients who are of reproductive potential agree to use an acceptable method of birth control throughout the study. Acceptable methods include an intrauterine device (IUD), diaphragm with spermicide, condoms, or abstinence.~6. HIV RNA \> 5000 copies/ml. No restriction on CD4 cell count.~7. A negative urine pregnancy test on the day of initiation of therapy.~Exclusion Criteria:~1. Prior treatment with \>1week of antiretroviral therapy.~2. Patient requires or is anticipated to require any of the prohibited medications noted in the protocol.~3. HIV RNA \< 5000 prior to receiving therapy.~4. Baseline resistance to any of the study regimen drugs on genotype testing.~5. Patients with acute hepatitis due to any cause or clinically significant chronic liver disease.~6. Patient with severe renal insufficiency defined as a calculated creatinine clearance at time of screening \<30mL/min, based on the Cockcroft-Gault equation which is as follows (and 0.85X this value for females): Clcr(mL/min) = (l40-age) x weight (in kg)72 x serum creatinine (mg/dL).~7. Patient has a condition (including but not limited to alcohol or other substance abuse) which in the opinion of the investigator would interfere with patient compliance or safety.~8. A female patient who is pregnant, breast-feeding, or expecting to conceive or donate eggs during the study; or a male patient who is planning to impregnate or provide sperm donation during the study is excluded.~9. Inability to obtain signed informed consent from a patient age 18 or older.~10. Patient has significant hypersensitivity or other contraindication to any of the components of the study drug.~11. Patients who should be treated for hyperlipidemia as per NCEPIII guidelines and patients who are currently receiving lipid-lowering therapy are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir plus Truvada (Type: EXPERIMENTAL): Raltegravir (400mg), 1 tablet, administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
- Lopinavir/Ritonavir plus Truvada (Type: ACTIVE_COMPARATOR): Lopinavir/Ritonavir (400mg/100mg) (Kaletra), 2 tablets administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).